First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer von Carbone, David P, Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M, Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T. Jeroen N, Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M, Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R, Villaruz, Liza C, Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J, Bhagavatheeswaran, Prabhu, Chen, Allen C, Socinski, Mark A

Volltext

Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemother... von Mądry, Radosław, Popławska, Lidia, Haslbauer, Ferdinand, Šafanda, Martin, Ghizdavescu, Doru, Benkovicova, Jana, Csőszi, Tibor, Mihaylov, Georgi, Niepel, Daniela, Jaeger, Christine, Frkanova, Iveta, Macovei, Alina, Staudigl, Christine

Volltext

Abstract 4606: Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC) von Shaw, Alice T., Ghizdavescu, Doru, Jain, Minish, Volovat, Constantin, Subramaniam, Deepa, Shuster, Dale, Jin, Xiaoping, Dutta, Dipen, Pai, Seema, von Roemeling, Reinhard

Volltext